ASP Isotopes 3Q 2026: Revenue $5.12M, EPS ($0.21) — 10-Q Summary
ASP Isotopes reported 3Q 2026 revenue of $5.12M, up 303% YoY, driven by radiopharmacy sales and new LNG revenue. However, net loss widened to $30.37M, with higher operating and interest expenses. Gross profit improved, but helium and LNG segment recorded a $0.8M loss. Isotope shipments are planned for 2026-2027, with LNG margins expected to improve in 2027.

